

Enamine's IDD Platform Boosts ABX-CRO's Translational Medicine Approach towards Imaging Agents and Radiopharmaceuticals

KYIV, UKRAINE, January 16, 2026 /EINPresswire.com/ -- ABX-CRO and Enamine initiated their cooperation in 2024. Since then, Enamine supports ABX-CRO with its integrated competencies in biology, chemistry, and computational sciences through its research centers in Frankfurt/Germany, Kyiv/Ukraine, and Wroclaw/Poland. The initial relationship proved to be highly productive, securing innovation in short research cycles and utilizing resources at its highest return on investment. In consequence of this success, ABX-CRO and Enamine continue to deepen their relationship for the future.

Enamine's profound knowledge of chemical space, namely with its REAL compounds, the world's largest collection of make-on-demand small molecules that represents a significant fraction of such synthetically accessible chemical space. Its member molecules are REadily AccessibLe through validated parallel synthesis protocols using qualified in-stock building blocks.

In combination with its expanded capabilities in medicinal chemistry and computer-aided drug design, and its optimized research logistics, Enamine accomplishes design-make-test-analyze cycles of small molecules in drug discovery within days rather than weeks. Enamine Germany in Frankfurt enables support of rapid lead optimization and project management. Enamine's capabilities in biology, from hit identification, lead optimization, and translating into preclinical proof-of-concept studies, are critically supported by its biology research centers in Kyiv and



